Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Goldman Sachs 44^th Annual Global Healthcare Conference in Dana Point, CA, on Thursday, June 15, 2023 at 8:40 a.m. PT.

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/ or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005750/en/

The Geron (Delaware) Stock at the time of publication of the news with a fall of -0,80 % to 3,333USD on Lang & Schwarz stock exchange (07. Juni 2023, 22:28 Uhr).